On turning 65, Paul Stamets reflects on mortality and argues that access to psilocybin at end of life should be an inalienable human right. He distinguishes between religious and spiritual responses to death, critiques recent drug prohibition as historically naive and morally indefensible, and calls for legalization of psilocybin therapy based on FDA findings that it is among the safest substances ever studied while producing dramatic therapeutic outcomes.
What does it mean to confront mortality at the threshold of your final decades?
Stamets opens with a simple, unavoidable premise: "There's two things certain in life—we are born and we die." This observation anchors what follows: a meditation on consciousness, spiritual autonomy, and the right to choose how one meets the end of life. At 65, Stamets finds himself at a boundary that demands reflection. The questions are ancient—where did we come from, where are we going—but his answer departs from conventional frameworks. He does not appeal to organized religion. Instead, he positions spirituality as a personal reckoning with existence, one that each person must undertake according to their own consciousness.
This distinction matters. Religion, for Stamets, offers one possible solution to age-old existential questions, but it is not universal. Some reject it outright. What remains constant across all worldviews, however, is the fact of mortality itself. Everyone dies, and everyone must come to terms with that fact in their own way. Stamets argues that this deeply personal work is not something society should criminalize or restrict.
How does the psilocybin experience change one's relationship with death?
Stamets describes a specific pharmacological outcome: "With the psilocybin experience, you suddenly know that you're part of a giant oneness, and it gives you context and consolation about your own mortality." This is not metaphorical language—he is describing a measurable shift in subjective experience and existential perspective. The compound does not merely relax anxiety; it appears to relocate the sense of individual self within a larger system of connection. That reframing provides what he calls "consolation"—not false comfort, but a form of peace grounded in the felt sense of participation in something larger than the isolated self.
For someone approaching the end of life, this shift in perspective carries clinical weight. End-of-life anxiety, existential dread, and the felt sense of isolation are documented drivers of suffering. If a substance can reliably produce a shift toward interconnection and acceptance, the question becomes: who has the right to deny it to someone facing death?
Why does Stamets call drug prohibition on psilocybin "immoral"?
Stamets makes a historical argument. Psilocybin-containing mushrooms "have been used for thousands, probably tens of thousands, maybe millions of years." They are not new drugs engineered in a laboratory. They are part of human history. Yet laws criminalizing their use are, in his framing, recent inventions—roughly 50 years old. "It's not only academically naive," he says, "it's immoral."
The force of this claim rests on several premises. First, a substance with a millennia-long human history of use cannot be written off as inherently dangerous or unprecedented. Second, laws created in the past 50 years to ostracize people for using these substances lack historical or ethical grounding. They are not based on age-old wisdom but on recent policy decisions. Third, and most critically, these laws operate to criminalize people at their most vulnerable—those seeking spiritual or psychological support at the end of life. Stamets argues this crosses a line: "Everyone has a right to how they're going to leave this life."
What does current FDA research say about psilocybin's safety profile?
Stamets cites a significant finding from FDA scientists: "They have never seen a safer drug with such dramatic impacts that requires such infrequent use." This statement deserves unpacking. It makes three claims simultaneously. First, psilocybin ranks exceptionally high for safety relative to other substances. Second, its therapeutic effects are substantial and measurable. Third, it requires infrequent dosing—a single or small number of sessions can produce lasting benefit. This combination—extreme safety, dramatic efficacy, and infrequent use—is vanishingly rare in pharmacology. Most drugs that are highly safe have modest effects; most drugs with dramatic effects carry greater risk. Psilocybin appears to break that pattern.
For end-of-life care, this profile has obvious implications. A single intervention, low-risk, with potential for substantial reduction in existential suffering and increase in peace makes particular sense in a context where ongoing long-term treatment is often not the goal.
Why does Stamets frame this as a civil rights issue?
By positioning access to psilocybin as "an inalienable right of passage," Stamets moves the conversation out of the medical or legal realm and into the ethical one. He is not simply arguing that psilocybin should be decriminalized because it is safe or effective. He is arguing that people have a fundamental right to their own consciousness and their own spiritual preparation for death. No external authority—not the state, not the medical establishment, not the majority—has the right to prohibit a person from using a low-risk substance to make peace with mortality.
This is a deliberate echo of language around bodily autonomy and self-determination. Just as many argue people have a right to make decisions about their own bodies and healthcare, Stamets argues people have a right to make decisions about their own consciousness and spiritual journey, especially at the end of life. Criminalizing that choice amounts to criminalizing the exercise of that right.
What is the practical next step Stamets advocates?
Stamets does not argue for unlimited access to all psychedelic substances. Instead, he calls for "a first step on the long path for full legalization"—the legalization of psilocybin specifically for end-of-life therapeutic use. This is a narrower, more achievable goal than full decriminalization. It also acknowledges that "we must be very disciplined and careful." The compounds are not without responsibility; they require skilled facilitation, proper set and setting, and informed consent. But none of those safeguards requires criminalization.
He also explicitly thanks organizations advancing this cause: Therapsil, Yes on IP34, MAPS (Multidisciplinary Association for Psychedelic Studies), and others working on legalization initiatives at local, provincial, state, and national levels. This is not abstract philosophy—it is a call for concrete political and legislative action.
How does Stamets distinguish between religious and spiritual responses to death?
Stamets states plainly: "Although I am not religious, I am spiritual." This is not a rejection of religion but a clarification of his own orientation. Religion, as he frames it, is one path among many to making sense of existence. Some people find it essential; others find it irrelevant ("someone else's rodeo"). What matters is not which framework someone chooses but that they have the freedom to choose.
This openness is crucial to his argument. He is not saying everyone should use psilocybin, or that it should be the only tool for end-of-life care, or that spirituality is superior to religion. He is saying that people deserve autonomy in how they approach mortality. For some that will be prayer, for some meditation, for some psilocybin. All should be available. None should be criminalized.
What larger point is Stamets making about our collective maturity?
He closes with a simple, powerful statement: "We are better than this." The implicit argument is that a society that criminalizes people seeking to come to peace with their own death has failed a basic test of moral evolution. "Hopefully we have evolved to respect each other's choice," he says, but makes clear that evolution is not automatic. It requires active support for legalization initiatives, active resistance to the criminalization of end-of-life autonomy, and a cultural shift in how we think about consciousness, death, and the right to one's own spiritual path.
Where to go from here
For those interested in this topic, Stamets points to several resources: paulstamets.com for his ongoing work; the FDA's own research on psilocybin as a "Breakthrough Therapy" for severe depression; and the organizations working on legalization (MAPS, Therapsil, Yes on IP34). The scientific basis for psilocybin's efficacy is solid and growing. The ethical argument for end-of-life autonomy is straightforward. What remains is the political and cultural work of moving policy in line with both the science and the ethics.
